Immuneering (NASDAQ:IMRX) PT Lowered to $8.00

Immuneering (NASDAQ:IMRXGet Free Report) had its target price lowered by analysts at Mizuho from $20.00 to $8.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Mizuho’s target price would indicate a potential upside of 233.33% from the company’s current price.

A number of other equities analysts have also recently commented on the company. Needham & Company LLC lowered their target price on Immuneering from $20.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 15th. TD Cowen reaffirmed a “market perform” rating on shares of Immuneering in a report on Friday, March 15th. Oppenheimer reissued an “outperform” rating and issued a $25.00 target price on shares of Immuneering in a report on Tuesday, March 5th. Chardan Capital reduced their price objective on Immuneering from $21.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $3.00 target price (down from $16.00) on shares of Immuneering in a research report on Friday, March 15th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.50.

View Our Latest Analysis on IMRX

Immuneering Price Performance

Shares of IMRX stock opened at $2.40 on Tuesday. The company has a market cap of $70.27 million, a price-to-earnings ratio of -1.27 and a beta of -0.89. The stock has a 50 day simple moving average of $5.16 and a 200-day simple moving average of $6.19. Immuneering has a 1-year low of $1.90 and a 1-year high of $14.29.

Immuneering (NASDAQ:IMRXGet Free Report) last posted its quarterly earnings data on Friday, March 1st. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). Analysts anticipate that Immuneering will post -1.89 earnings per share for the current fiscal year.

Insider Activity

In other Immuneering news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $2.90, for a total transaction of $1,160,000.00. Following the completion of the sale, the insider now owns 2,895,273 shares in the company, valued at approximately $8,396,291.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of Immuneering stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $2.90, for a total value of $1,160,000.00. Following the completion of the transaction, the insider now owns 2,895,273 shares in the company, valued at approximately $8,396,291.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Peter Feinberg bought 25,000 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was purchased at an average price of $2.55 per share, with a total value of $63,750.00. Following the transaction, the director now owns 111,766 shares in the company, valued at approximately $285,003.30. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 111,790 shares of company stock worth $266,645. 23.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Immuneering

Hedge funds have recently made changes to their positions in the stock. Cormorant Asset Management LP lifted its holdings in Immuneering by 76.2% in the second quarter. Cormorant Asset Management LP now owns 4,204,364 shares of the company’s stock worth $42,632,000 after purchasing an additional 1,818,183 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Immuneering by 16.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,142,829 shares of the company’s stock valued at $22,413,000 after buying an additional 577,356 shares in the last quarter. BlackRock Inc. boosted its position in Immuneering by 80.8% during the second quarter. BlackRock Inc. now owns 2,423,658 shares of the company’s stock worth $24,576,000 after purchasing an additional 1,083,465 shares during the period. Citadel Advisors LLC boosted its position in Immuneering by 1.8% during the second quarter. Citadel Advisors LLC now owns 2,199,209 shares of the company’s stock worth $11,898,000 after purchasing an additional 39,777 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Immuneering by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company’s stock valued at $7,893,000 after acquiring an additional 29,963 shares during the period. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

(Get Free Report)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

Featured Articles

Analyst Recommendations for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.